Citra Anticoagulants Announces FDA Approval for NO CLOT-50, ACD-AMay 13, 2011 No Comments
Braintree, MA (PRWEB) November 23, 2004
Citra Anticoagulants, Inc. announces its parent company, Cytosol Laboratories, Inc., has received U.S. Food and Drug Administration (FDA) approval for NO CLOT-50 Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., commonly known as ACD-A, for use in the extracorporeal blood processing with Autologous Platelet Rich Plasma (PRP) Systems in the production of platelet rich plasma. NO CLOT-50 is the anticoagulant of choice to prevent clotting of the whole blood during the extracorporeal blood processing with Autologous PRP Systems.
NO CLOT-50 is a United States Pharmacopeia formulated product containing 50 milliliters of ACD-A. NO CLOT-50 prevents the coagulation of blood by virtue of its citrate ions ability to chelate the ionized calcium present in blood to form a non-ionized calcium-citrate complex. When the total dose of citrate ions is greater than the total amount of ionized calcium, blood clotting is prevented.
NO CLOT-50 is marketed and distributed exclusively by Citra Anticoagulants, Inc.
About Citra Anticoagulants
Headquartered in Braintree, Massachusetts, Citra Anticoagulants, Inc., is a wholly-owned subsidiary of Cytosol Laboratories, Inc., a privately held company, which develops and manufactures sterile, medical solutions. Citra Anticoagulants markets and distributes various citrate-based anticoagulants to a multitude of markets within the medical community.
Citra Anticoagulants, Inc.
Ronald H. Lewis, Ph.D., President
Adrienne Summers, Team Customer
# # #